<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - PROPOFOL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>PROPOFOL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Induction of anaesthesia using 0.5% or 1% injection</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults 18&#8211;54 years</strong><br/>
                Usual dose 1.5&#8211;2.5 mg/kg, to be administered at a rate of 20&#8211;40 mg every 10 seconds until response, for debilitated patients use dose for 55 years and over.</li>
              <li class="dose adult"><strong>For adults 55 years and over</strong><br/>
                Usual dose 1&#8211;1.5 mg/kg, to be administered at a rate of 20 mg every 10 seconds until response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Induction of anaesthesia using 2% injection</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults 18&#8211;54 years</strong><br/>
                Usual dose 1.5&#8211;2.5 mg/kg, to be administered at a rate of 20&#8211;40 mg every 10 seconds until response. For debilitated patients use dose for 55 years and over.</li>
              <li class="dose adult"><strong>For adults 55 years and over</strong><br/>
                Usual dose 1&#8211;1.5 mg/kg, to be administered at a rate of 20 mg every 10 seconds until response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Maintenance of anaesthesia using 1% injection</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Usual dose 4&#8211;12 mg/kg/hour, alternatively (by slow intravenous injection) 25&#8211;50 mg, dose may be repeated according to response, for debilitated patients use dose for elderly.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Usual dose 3&#8211;6 mg/kg/hour, alternatively (by slow intravenous injection) 25&#8211;50 mg, dose may be repeated according to response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Maintenance of anaesthesia using 2% injection</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Usual dose 4&#8211;12 mg/kg/hour, for debilitated patients use dose for elderly.</li>
              <li class="dose adult"><strong>For adults elderly</strong><br/>
                Usual dose 3&#8211;6 mg/kg/hour.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Sedation of ventilated patients in intensive care using 1% or 2% injection</span>,
            </h4>
            <p class="specificity"><span class="route">By continuous intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Usual dose 0.3&#8211;4 mg/kg/hour, adjusted according to response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Induction of sedation for surgical and diagnostic procedures using 0.5% or 1% injection</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 0.5&#8211;1 mg/kg, to be administered over 1&#8211;5 minutes, dose and rate of administration adjusted according to desired level of sedation and response.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Maintenance of sedation for surgical and diagnostic procedures using 0.5% injection</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1.5&#8211;4.5 mg/kg/hour, dose and rate of administration adjusted according to desired level of sedation and response, followed by (by slow intravenous injection) 10&#8211;20 mg, (if rapid increase in sedation required), patients over 55 years or debilitated may require lower initial dose and rate of administration.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Maintenance of sedation for surgical and diagnostic procedures using 1% injection</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 1.5&#8211;4.5 mg/kg/hour, dose and rate of administration adjusted according to desired level of sedation and response, followed by (by slow intravenous injection) 10&#8211;20 mg, (if rapid increase in sedation required), patients over 55 years or debilitated may require lower initial dose and rate of administration.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Maintenance of sedation for surgical and diagnostic procedures using 2% injection</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 1.5&#8211;4.5 mg/kg/hour, dose and rate of administration adjusted according to desired level of sedation and response, followed by (by slow intravenous injection) 10&#8211;20 mg, using 0.5% or 1% injection (if rapid increase in sedation required), patients over 55 years or debilitated may require lower initial dose and rate of administration.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>May depress neonatal respiration if used during delivery.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Use with caution.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Use with caution.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Headache, hypotension, tachycardia, transient apnoea,
              </p>
              <p>
                <strong>uncommon:</strong> Phlebitis, thrombosis,
              </p>
              <p>
                <strong>rare:</strong> Anaphylaxis, arrhythmia, convulsions (onset can be delayed), delayed recovery from anaesthesia, euphoria,
              </p>
              <p>
                <strong>veryRare:</strong> Discoloration of urine, pancreatitis, pulmonary oedema, sexual disinhibition,
              </p>
              <p>
                <strong>notKnown:</strong> Bradycardia, pain on intravenous injection, propofol infusion syndrome, significant extraneous muscle movements,
              </p>
        
        
            <section class="advice">
                <h3>Bradycardia</h3>
              <p>Bardycardia may be profound and may be treated with intravenous administration of an antimuscarinic drug.</p>
            </section>
            <section class="advice">
                <h3>Extraneous muscle movement</h3>
              <p>Extraneous muscle movements can be minimised by an opioid analgesic or a short-acting benzodiazepine given just before induction.</p>
            </section>
            <section class="advice">
                <h3>Pain on injection</h3>
              <p>Can be reduced by intravenous lidocaine.</p>
            </section>
            <section class="advice">
                <h3>Propofol infusion syndrome</h3>
              <p>Prolonged infusion of propofol doses exceeding 4&#8239;mg/kg/hour may result in potentially fatal effects, including metabolic acidosis, arrhythmias, cardiac failure, rhabdomyolysis, hyperlipidaemia, hyperkalaemia, hepatomegaly, and renal failure.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Shake before use; microbiological filter not recommended; may be administered via a Y-piece close to injection site co-administered with Glucose 5% <i>or</i> Sodium chloride 0.9%.</p><p>0.5% <b>emulsion</b> for injection or intermittent infusion; may be administered undiluted, or diluted with Glucose 5% <i>or</i> Sodium chloride 0.9%; dilute to a concentration not less than 1&#8239;mg/mL.</p><p>1% <b>emulsion</b> for injection or infusion; may be administered undiluted, or diluted with Glucose 5% (<i>Dipravan</i>
            <tm tmtype="reg"/>) or (<i>Propofol-Lipuro</i>
            <tm tmtype="reg"/>) <i>or</i> Sodium chloride 0.9% (<i>Propofol-Lipuro</i>
            <tm tmtype="reg"/> only); dilute to a concentration not less than 2 mg/mL; use within 6 hours of preparation.</p><p>2% <b>emulsion</b> for infusion; do not dilute.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <p>Propofol should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Acute circulatory failure (shock)
          </li>
          <li>
            cardiac impairment
          </li>
          <li>
            cardiovascular disease
          </li>
          <li>
            elderly
          </li>
          <li>
            epilepsy
          </li>
          <li>
            fixed cardiac output
          </li>
          <li>
            hypotension
          </li>
          <li>
            hypovolaemia
          </li>
          <li>
            raised intracranial pressure
          </li>
          <li>
            respiratory impairment
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor blood-lipid concentration if risk of fat overload or if sedation longer than 3 days.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of PROPOFOL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75990"><a href="../medicinalForm/PHP75990.html" data-target="#PHP75990" data-action="load">Emulsion for injection</a></div>
            <div id="PHP75985"><a href="../medicinalForm/PHP75985.html" data-target="#PHP75985" data-action="load">Emulsion for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
